E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nutritional and Metabolic Diseases [C18] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10067585 |
E.1.2 | Term | Type 2 diabetes mellitus |
E.1.2 | System Organ Class | 10027433 - Metabolism and nutrition disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary endpoint in this study is the change from baseline in Glycosylated haemoglobin A1c (HbA1c) after 18 weeks of treatment. Throughout the study protocol, the term "baseline" refers to the observation at the randomization visit (Visit 3) prior to treatment. |
|
E.2.2 | Secondary objectives of the trial |
Key secondary endpoints:
• Change from baseline in dose of basal insulin dose after 78 weeks of treatment
• Change from baseline in HbA1c after 78 weeks of treatment
Secondary endpoints
• The occurrence of treat to target efficacy response, that is an HbA1c under treatment of <7.0% after 18, 54 and 78 weeks of treatment
• Occurrence of relative efficacy response (HbA1c lowering by at least 0.5% after 18, 54 and 78 weeks of treatment
• Change from baseline in HbA1c after 54 weeks of treatment
• Change from baseline in dose of basal insulin dose after 54 weeks of treatment
• The change from baseline and percent change from baseline in fasting plasma glucose (FPG) after 18, 54, and 78 weeks of treatment |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Signed and dated written informed consent by date of Visit 1 in accordance with Good Clinical Practice (GCP) and local legislation
• Male and female patients with a diagnosis of T2DM treated with basal glargine or detemir insulin (≥20 IU/day) or NPH insulin (≥14 IU/day) with or without concomitant metformin and / or sulfonylurea. The total insulin dose should not be changed by more than 10% of the baseline value within the 12 weeks prior to randomization. The oral anti-diabetic therapy has to be unchanged for at least 12 weeks prior to randomization.
• HbA1c of >7.0% and ≤10% at Visit 1 (screening)
• Suitability for trial participation according to investigator's judgment (evaluating all
alternative treatment options and in consideration of the patient completing the study)
• Age ≥18 years at Visit 1 (screening)
• BMI ≤45 kg/m2 (Body Mass Index) at Visit 1 (screening) |
|
E.4 | Principal exclusion criteria |
Clinical conditions that might interfere with the subject's ability to participate in the trial include, but are not limited to, the following:
• Uncontrolled hyperglycemia with a glucose level >240 mg/dl (>13.3 mmol/L) after an overnight fast or >400 mg/dl (>22.2 mmol/L) in a randomly performed measurement during placebo run-in and confirmed by a second measurement (not on the same day).
• Frequent (at the discretion of the investigator) episodes of hypoglycemic events on
basal insulin therapy
• Myocardial infarction, stroke, or Transient Ischemic Attack (TIA) within 3 months
prior to obtaining informed consent
• Impaired hepatic function, defined by serum levels of either ALT (SGPT), AST
(SGOT), or alkaline phosphatase (ALP) above 3 times the upper limit of normal
ULN) as determined at Visit 1
• Impaired renal function, defined as GFR <30 ml/min
• The metformin or sulfonylurea that you’re taking is not being used in accordance with local prescribing information.
• Any contraindications to the background basal insulin (glargine, detemir, or NPH)
according to the local label
• Known hypersensitivity or allergy to the investigational product BI 10773 or its
excipients
• Treatment with any other oral anti-diabetic medications, other than metformin and / or sulfonylurea therapy, within 3 months of obtaining informed consent
• Patients with a history of having received chronic short acting insulin, a
Glycogen-like peptide – 1 (GLP-1) analogue, or an Amylin agonist, within 3 months
of signing informed consent
• Gastric bypass surgery or any other gastrointestinal surgery that may induce
mal-absorption
• Treatment with anti-obesity drugs (e.g., including but not limited to sibutramine,
orlistat, or rimonabant) 3 months prior to informed consent
• Current treatment with systemic steroids at time of informed consent or change in
dosage of thyroid hormones within 6 weeks prior to informed consent
• Patients with history of any cancer within last 5 years with the exception of basal cell and squamous cell skin cancer
• Pre-menopausal women (last menstruation ≤1 year prior to informed consent) who: are nursing their infant or pregnant or are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study
• Alcohol or drug abuse within the 3 months prior to informed consent that would
interfere with trial participation
• Blood dyscrasias or any disorders causing hemolysis or unstable red blood cells (e.g., hemolytic anemia, thalassemias, sickle cell disease, hemochromatosis with routine phlebotomy treatment, malaria). An accurate HbA1c can not be established in patients with hemolysis
• Participation in another trial with an investigational drug within 2 months prior to
informed consent |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint in this study is the change from baseline in Glycosylated haemoglobin A1c (HbA1c) after 18 weeks of treatment. Throughout the study protocol, the term "baseline" refers to the observation at the randomization visit (Visit 3) prior to treatment. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | Yes |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 41 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Defined in the protocol page 62.
For all patients a follow-up visit (Visit 12) should be performed via telephone by the
investigator 7 days post-treatment
In case of premature discontinuation from the treatment period, at the time of discontinuation complete Visit 11 procedures followed by a telephone visit 7 days post-clinic visit (Visit 12).
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 11 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 11 |
E.8.9.2 | In all countries concerned by the trial days | 0 |